The European Commission approved Novo Nordisk’s once-daily oral version of Wegovy. This is the first oral GLP-1 treatment for weight management in the European Union.
The pill offers a needle-free alternative to weekly injections for adults with obesity. This approval escalates competition in the multi-billion dollar obesity market.
Eli Lilly currently markets the injectable rival Zepbound. Eli Lilly is also developing a daily oral treatment called orforglipron. Novo Nordisk’s early approval may challenge Eli Lilly’s growth and market share.